Aptose Biosciences Inc.
Home
About
Overview
Management Team
Board of Directors
Scientific Advisory Board
Product Pipeline
Overview
Luxeptinib for B-cell Tumors
Luxeptinib for Myeloid Tumors
HM43239 for AML
Posters & Presentations
Clinical Trials
Overview
Luxeptinib for CLL & NHL
Luxeptinib for AML
HM43239 for AML
Expanded Access
News
Press Releases
Presentations
Events
Investors
Overview
News & Events
Company Info
Financial Info
Stock Data
SEC Filings
SEDAR
Governance
Careers
Contact
Contact Us
Clinical Trials
Clinical Trials
Overview
Luxeptinib for CLL & NHL
Luxeptinib for AML
HM43239 for AML
Expanded Access
First Name
Last Name
Email
Clinical Trial
Select a trial
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Comments:
Submit